Business
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
STATEN ISLAND, N.Y., March 17, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"STATEN ISLAND, N.Y., March 17, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2021. \nHighlights of the fourth quarter and full year ended December 31, 2021 include:\nAcurx is currently enrolling patients in a Phase 2b clinical trial, which will include up to 16 U.S. sites, in patients with C. difficile infection (CDI) with enrollment expected to be completed in the second half of 2022; The Phase 2b clinical trial will compare the efficacy of oral ibezapolstat, the Company's lead antibiotic candidate, to oral vancomycin, the current standard of care for CDI. Additional microbiome data from the Phase 2a trial of ibezapolstat in patients with CDI were presented at three prominent scientific conferences throughout 2021; Through its collaboration with University of Houston, the Company commenced a laboratory study of ibezapolstat to build upon the favorable microbiome data from the Company's Phase 1 and Phase 2a clinical trials. This new study will compare the impact of ibezapolstat on the microbiome as compared with other commonly used antibiotics to treat patients with CDI, namely, fidaxomicin, vancomycin, and metronidazole and the Company anticipates completing this study in the second half of 2022; The Phase 2a trial demonstrated 100% clinical cure and 100% sustained clinical cure with ibezapolstat along with beneficial microbiome changes during treatment including overgrowth of Actinobacteria and Firmicutes phylum species while on therapy and new findings which demonstrate potentially beneficial effects on bile acid metabolism; These reported clinical results support the expectation that microbiome effects may be predictive of beneficial patient outcomes including low rates of recurrence; The previously announced R&D program in collaboration with Leiden University Medical Center in Holland is ongoing to further evaluate the mechanism-of-action of Acurx's inhibitors against the DNA pol IIIC enzyme, which is the bacterial target of the Company's antibiotic product pipeline. Fourth Quarter and Full Year 2021 Financial Results\nResearch and develop...